IKT Stock Analysis: Buy, Sell, or Hold?
IKT - Inhibikase Therapeutics, Inc. Common Stock
$2.42
0.02 (0.83%)
▲
5d:
+0.41%
30d:
+17.48%
90d:
+27.37%
WAIT
LOW Confidence
Analysis Updated: Aug 13, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When IKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: IKT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: IKT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: IKT is currently trading at $2.42, which is considered extended relative to its 30-day fair value range of $2.07 to $2.39.
Technical Outlook: Technically, IKT is in a strong uptrend. Immediate support is located at $2.13, while resistance sits at $2.52.
Market Sentiment: IKT scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+150.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IKT is in a strong uptrend. Immediate support is located at $2.13, while resistance sits at $2.52.
Market Sentiment: IKT scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+150.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.07 -
$2.39
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 150.0% below Wall St target ($6.00)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.07 -
$2.39
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.13
Resistance Level
$2.53
Current Trend
Strong Uptrend
Technical data as of
Aug 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.81
Wall Street Target
$6.00
(+150.0%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 13, 2026 2:28 PM ET
Data refreshes hourly during market hours. Next update: 3:28 PM
Data refreshes hourly during market hours. Next update: 3:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$376 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$431 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 52 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$559 | 27 SELL |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
